Stocks · News reference
ICON shares are trading higher after the company reported better-than-expected Q2 financial results.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
UBS Reinstates Neutral on Icon, Announces $195 Price Target
Rare Disease Contract Research Organization (CRO) Market Outlook 2026-2030: Investment Trends, Strategic Profiles and Revenue Share Outlook
The global rare disease CRO market is projected to grow from $2.07 billion in 2025 to $3.16 billion by 2030, with an 8.9% CAGR. Growth is driven by expanding gene and cell therapy pipelines, increasing orphan drug approvals, precision medicine adoption, and decentralized clinical trials. Key trends include AI integration, patient registries, and real-world evidence utilization.
Citigroup Maintains Neutral on Icon, Lowers Price Target to $175
Citigroup analyst Albert Hu maintains Icon (NASDAQ:ICLR) with a Neutral and lowers the price target from $180 to $175.